Skip to main content

Table 2 Fitted vaccine RTS,S properties

From: The public health impact of malaria vaccine RTS,S in malaria endemic Africa: country-specific predictions using 18 month follow-up Phase III data and simulation models

Cohorts Initial efficacy Half-life (exponential decay)
6-12 week 62.7 % 1.12 years
cohort (with 95 % CI 39.5-80.3 %) (with 95 % CI 1-1.43 years)
5-17 month 79.2 % 1.12 years
cohort (with 95 % CI 67.3-84.8 %) (with 95 % CI 1-1.43 years)